ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2630

Utility of the Korean Version of Systemic Lupus Activity Questionnaire, in Clinical Practice: Its Correlation with Disease Activity Indices of Systemic Lupus Erythematosus

Eun Young Ahn1, Wonho Lee2, Jin Young Moon2, Jin Kyun Park2, Eun Young Lee3, Eun Bong Lee2, Sang-Cheol Bae4 and Kichul Shin5, 1Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Korea, Republic of (South), 4Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 5Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Activity score, questionnaires and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Assessing patient-reported outcomes validated to be associated with disease activity has helped clinicians better understand treatment response of patients with systemic rheumatic disease. Such questionnaire for systemic lupus erythematosus (SLE) are rarely used in daily practice; the utility of out-patient targeted questionnaire for SLE has never been studied in Korea.

Methods: The Systemic Lupus Activity Questionnaire, or SLAQ, was translated in Korean (K-) and back-translated, then reviewed by a committee specifically organized for this purpose. This K-SLAQ was then applied to SLE patients followed (out-patient) at institute 1 (SMG-SNU); SELENA-SLEDAI and Systemic Lupus Activity Measure (SLAM)-R was measured on the same day. K-SLAQ was measured again 2 weeks later to assess its reliability. Finally, K-SLAQ was validated in the same manner at a separate institute (2, SNUH). The receiver operating characteristic (ROC) curve was obtained to study K-SLAQ cut-off values in relation to those indicating high disease activity in SELENA-SLEDAI and SLAM-R.

Results: Forty-two patients were enrolled at institute 1, where the median (min-max) age of patients were 40 (19-70), and disease duration was 3.0 (0-18.1) years. The mean K-SLAQ, SELENA-SLEDAI, SLAM-R values were 10 (10-29), 7 (0-26), 5 (1-18), respectively. The correlation between K-SLAQ and the disease activity indices are depicted in the presented table. These results were validated at institute 2 (N= 44). The interclass correlation between repeated K-SLAQ measures was 0.912 (95% CI 0.847-0.949, p< 0.0001), and the area under the ROC curve of SLAQ for SELENA-SLEDAI ©ø 6 was 0.705 (95% CI 0.59-0.82, p= 0.002), and SLAM-R ©ø 7 was 0.704 (95% CI 0.595-0.812, p= 0.001).

Conclusion: K-SLAQ is a useful tool which correlated well with commonly used SLE disease activity indices. This may also facilitate identifying key determinants of flares in daily clinical practice.

 

Table. Correlation between SLAQ and SELENA-SLEDAI or SLAM

 

 

Institute 1

 

 

Institute 2

 

Measures

SELENA-SLEDAI

SLAM-R

SLAM-R nolab

SELENA-SLEDAI

SLAM-R

SLAM-R nolab

r

p-value

r

p-value

r

p-value

r

p-value

r

p-value

r

p-value

SLAQ

0.439

0.004

0.575

< 0.001

0.595

< 0.001

0.317

0.036

0.389

0.009

0.545

< 0.001

Symptom score

0.446

0.003

0.591

< 0.001

0.587

< 0.001

0.265

0.082

0.333

0.027

0.498

0.001

Patient global assessment

0.174

0.271

0.259

0.098

0.217

0.168

0.341

0.024

0.255

0.094

0.212

0.168

Patient NRS

0.272

0.082

0.303

0.051

0.396

0.009

0.34

0.024

0.309

0.042

0.307

0.042

r, Spearman¡¯s coefficient; NRS, numerical rating scale

 


Disclosure: E. Y. Ahn, None; W. Lee, None; J. Y. Moon, None; J. K. Park, None; E. Y. Lee, None; E. B. Lee, None; S. C. Bae, None; K. Shin, None.

To cite this abstract in AMA style:

Ahn EY, Lee W, Moon JY, Park JK, Lee EY, Lee EB, Bae SC, Shin K. Utility of the Korean Version of Systemic Lupus Activity Questionnaire, in Clinical Practice: Its Correlation with Disease Activity Indices of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/utility-of-the-korean-version-of-systemic-lupus-activity-questionnaire-in-clinical-practice-its-correlation-with-disease-activity-indices-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-the-korean-version-of-systemic-lupus-activity-questionnaire-in-clinical-practice-its-correlation-with-disease-activity-indices-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology